Innate Pharma highlights abstracts selected for EHA 2024 congress
Innate Pharma reports first quarter 2024 business update and financial results
Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579/IPH6101 progressing to Phase 2 for blood cancer patients
Innate Pharma presents at AACR 2024 preclinical efficacy of its pre-IND drug candidate IPH45, a novel Nectin-4 Antibody Drug Conjugate
Innate Pharma reports Full Year 2023 financial results and business update
Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024
First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Innate Pharma announces U.S. FDA lifts partial clinical hold on lacutamab clinical program
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi
Innate Pharma shares efficacy and safety Phase 1 /2 results of NK Cell Engager SAR443579 / IPH6101 developed by Sanofi at ASH 2023
